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Black men have higher prostate cancer incidence and mortality compared to white men. Both 
biological and socioeconomical factors contribute to the disparity in prostate cancer mortality. Fewer 
studies focus on the racial disparity in advanced prostate cancer compared to that of early disease. 
Data from clinical trials provide an opportunity to study racial disparity in cancer outcome in a 
controlled setting. Generating evidence on the racial disparity in advanced prostate cancer outcome 
from clinical trial data could help understand the disease and lead to more precise treatment 
guidelines. 
 
Materials and Methods 
Individual patient data of black and white men who received docetaxel from the comparator arm of 
four phase III CRPC trials [ASCENT2 (NCT00273338), VENICE (NCT00519285), ENTHUSE-M1C 
(NCT00617669), and MAINSAIL (NCT00988208)]. Comparison of overall survival (OS) between 
black vs white men was performed by the Kaplan-Meier method, log-rank test, and mixed-effect Cox 
models. The prognostic value of PSA response was assessed by mixed-effect Cox models. Incidence 
of PSA response was assessed by mixed-effect logistic regression models. Missing lab data was 
imputed using the Markov chain Monte Carlo method.  
 
Results 
A total of 1817 patients were included in the analysis; 1721 (94.7%) were white and 96 (5.3%) were 
black. No difference in OS by race was detected by log-rank test (P=0.708). The hazard ratio of death 
comparing black to white men was 0.86 (95% CI 0.62-1.19, P=0.339) after adjusted by age, trial of 
enrolment, site of metastases, prior treatment and baseline lab data. The hazard ratio of death 
comparing patients with and without PSA response was 0.78 (95% CI 0.42-1.45, P=0.423) in black 
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men and 0.54 (95% CI 0.47-0.62, P<0.001) in white men. The incidence of PSA response was higher 
in black men compared to that in white men (odds ratio 1.30, 95% CI 1.17-1.46, P<0.001). 
 
Conclusions 
In the 4 CRPC trials, OS in black men was insignificantly longer to that of white men. PSA response 
was a strong favorable prognostic indicator in white men, but not found in blacks. Black men had a 
significantly higher incidence for having PSA response. 
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In the United States, prostate cancer is the most common cancer and the third leading cause 
of cancer death in men, accounting for more than 170,000 new cases and 30,000 deaths 
annually 1. Racial disparities in prostate cancer incidence and mortality, especially between 
black and white men are well recognized. Black men have a higher prostate cancer incidence 
(157.6 vs 93.9 per 100,000 in 2015) and mortality (37.5 vs 17.7 per 100,000 in 2015)  
compared to white men in the US 2 1. Between 2010 and 2012, the lifetime risk of developing 
and dying from prostate cancer was 18.2% and 4.4% in black men, whereas the risks were 
13.3% and 2.4% in white men 2. The age of prostate cancer diagnosis was found to be earlier 
in black men compared to white men 3,4, and prostate cancer transforms to aggressive disease 
earlier in black men 5. In addition to earlier development of aggressive disease, higher 
pathologic upgrading rate and biochemical recurrence after definitive treatment in lower risk 
groups could be potential explanations of the higher mortality rate in black men 6-8. Prior 
studies found that the expression of genes associated with prostate cancer and tumor 
immunology, as well as the location of the tumors,  were different between black and white 
men, indicating that biological difference could contribute to the racial disparity in prostate 
cancer outcome 9-11. Socioeconomic factors could also play a role, as the differences between 
black and white men in the intensity of prostate-specific antigen (PSA) 
screening/surveillance, access to and choice of treatment, and diet between black and white 
men partially explains the gap in prostate mortality 12.13.  
 
Prior studies on the racial disparity in prostate cancer outcome heavily focused on localized 
disease, whereas evidence on advanced prostate cancer remains limited. Polednak compared 
the survival of 24,136 white men and 3,817 black men with late-stage (defined as disease that 
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spread beyond the prostatic capsule) prostate cancer using data from the Surveillance, 
Epidemiology, and End Result (SEER) program 14. The hazard ratio (HR) for prostate cancer 
death comparing black to white patients was 1.44 (95% Ci 1.35-1.53). After adjusting for 
age, disease extent, marital status and surgery, the effect of race became non-significant (HR 
1.05 95% CI 0.99-1.12). Despite that the study had a substantial sample size, it did not adjust 
for known clinical prognostic factors, such as Gleason score, PSA level, response to 
androgen-deprivation therapy, and other socioeconomic information. The quality of the data 
also depended on the accuracy of the SEER codes. These are common issues using registry 
data. To further isolate the biological and socioeconomic effects that contribute to the racial 
disparity in advanced prostate cancer outcome, a well-controlled setting is required. 
 
Data from clinical trials provide an opportunity to study racial disparity in prostate cancer 
outcome in a controlled setting. Patients enrolled in clinical trials are more homogenous in 
disease status and baseline characteristics, allowing the effect of race to be isolated more 
easily. The information collected in clinical trials is often more reliable and complete, which 
allows detailed adjustment for covariables and lead to higher validity 15. The major challenge 
of using clinical trial data to address racial disparity in prostate cancer is the racial 
composition of prostate cancer trial participants. Less than 10% of the study participants were 
nonwhite in the market approval of prostate cancer trials between 1993 and 2013 16. While 
comprising approximately 15% of newly diagnosed prostate cancer cases in the US, only 
around 5% of prostate cancer clinical trial participants were black men 16,17. Possible reasons 
for the underrepresentation of black men in cancer trials include lack of trust between the 
minority patients and the medical community, negative beliefs about participation in clinical 
trials, lack of knowledge regarding clinical trials, influence of healthcare providers on trial 
participation, and recommendation from friends or relatives with prior experience of 
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participation 16,18,19. To have a reasonable sample size for examining the racial disparity in 
prostate cancer outcome often requires pooling of multiple clinical trial data.  
 
A small number of studies compared the outcome between black and white men with 
advanced prostate cancer using clinical trial data. Thompson et al. analyzed data from 288 
African-American and white men in the Southwest Oncology Group Study (SWOG) 8894, in 
which orchiectomy with or without flutamide was compared in men with metastatic prostate 
cancer. After adjusting for performance status, age, Gleason score, and PSA level, African-
American men had a significantly unfavorable OS compared to white men (HR 1.23, 95% CI 
1.04-1.47, p=0.018) 20. Catherine et al. have drawn a similar conclusion in a study using 
patient data from SWOG 8894 and SWOG 9346 21. Among the 2,587 men with metastatic, 
hormone-naive prostate cancer included in the analysis, 504 (19%) were African-American 
men. The HR for death comparing African-American to non-African-American men was 1.30 
(95% CI 1.10-1.54, p=0.003) after adjusting for disease extent, pain, PSA level, age, 
performance status, Gleason score, and weight. However, results from three studies suggested 
a possible opposite effect of race in patients with metastatic castration-resistant prostate 
cancer (mCPRC). Halabi et al. pooled data from four phase III and four phase II CRPC trials 
conducted by the Cancer and Leukemia Group B (CALGB) to analyze racial disparity on 
survival. After adjusting for known prognostic variables, no statistically difference in Overall 
survival (OS) was found between black and white men, although black men had a slightly 
lower risk for death (HR for death 0.85, 95% CI 0.71-1.02, p=0.08) 22. Another study 
conducted by the same group that included eight CALGB CRPC trials found that black race 
was a favorable prognostic factor (HR 0.77, 95% CI 0.65-0.91, p=0.004) 23. In the two pooled 
analyses mentioned above, patient received various treatment; therefore, the effect of the 
treatment could confound the results. While we are doing working on the present study, a 
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study that addressed the effect of race on survival following docetaxel treatment was 
published 24. Among 500 black and 7,528 white patients with CRPC who were assigned to 
docetaxel and prednisolone treatment from nine phase III clinical trials, black men had a 
lower risk of death compared to white men (HR 0.81, 95% CI 0.72-0.91, p<0.001) after 
adjusting for age, PSA, performance status, alkaline phosphatase (ALP), hemoglobin (Hb) 
and site of metastases. The effect was even more prominent in four National Clinical Trial 
Network trials, which included 287 black men and 2,022 white men (HR 0.71, 95% CI 0.58-
0.87, p<0.001). These findings raise the question of whether racial disparity in prostate 
cancer outcome differs across the disease course. We would also like to understand the 
interactions between effect of race and important prognostic factors (i.e. age and visceral 
metastasis) on survival, which were not explored in prior studies. Further investigation is 
warranted to understand the mechanism behind the racial disparity in CRPC outcome.  
 
The dynamics of PSA after treatment is widely recognized as a prognosis indicator in 
advanced prostate cancer, but whether it could serve as a surrogacy remains controversial. An 
analysis based on the data from the SWOG 9916 trial found that a ≥30% decrease of PSA 
was associated with a 50% decrease of risk of death 25. Armstrong et al. found that PSA 
decline was highly prognostic in the TAX327 trial, but it was a weak surrogate for survival 
after taking the effect of treatment into account 26. Another study, which collected 2,161 
individual patients’ data from studies comparing bicalutamide to castration in patients with 
metastatic prostate cancer, concluded that time to PSA progression, PSA decline ≥50% and 
PSA normalization were prognostic indicators, but not ideal surrogates for OS 27. In a study 
by Francini et al., which included data from 22 clinical trials using docetaxel-based first-line 
therapy for CRPC, found a statistically significant but low correlation between PSA response 
rate and OSl (correlation coefficient ρ=0.50, 95% CI 0.47-0.88, p=0.003) 28. Replacing OS 
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with PSA dynamic parameters as the primary endpoint of prostate cancer clinical trials is not 
generally accepted 29. Despite the controversy on the surrogacy value of these PSA 
indicators, assessing differences between blacks and whites in the dynamics of PSA response 
could potentially help us understand the racial disparity in advanced prostate cancer outcome.  
 
In the present study, we aimed to compare the OS of black and white men with CRPC using 
clinical trial data to evaluate if there is racial disparity in the effect of docetaxel treatment on 
CRPC outcome. In order to understand whether the effect of race differs across patient 
groups, we explored the interaction between race and important prognostic variables (age and 
extent of the disease) on OS. Another aim of our study was  to explore the possible 
mechanisms of racial disparity in CRPC outcome by examining PSA response, which is 
defined as a 50% decrease of PSA from baseline from two consecutive tests ≥3 weeks apart 
within 12 weeks of treatment initiation 30. 
 
 
2 Materials and Methods 
2.1 Source of the dataset 
All the data in this study were obtained from Project Data Sphere. Project Data Sphere is an 
independent, nonprofit organization, which serves as a platform for researchers to share and 
analyze historical, individual-level phase III oncology trial comparator arm data. The site 
does not provide data from the experimental arms of the trials.  The platform is accessible to 
academic institutions, hospitals, and life science company affiliates, as well as independent 
researchers. The organization is operated and funded by the CEO Roundtable on Cancer’s 
Life Sciences Consortium31.  
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2.2 Study Population 
Clinical trials available on Project Data Sphere, which enrolled metastatic CRPC patients 
treated with docetaxel, and who had not received prior chemotherapy were selected for 
analysis. To further minimize the heterogeneity of the study population trials having 
additional therapeutic agents other than a placebo in the comparator arm were excluded. 
 
2.3 Data harmonization 
Project Data Sphere provides researchers de-identified, individual-level trial data. The 
content and format of the datasets vary among clinical trials. A master dataset was created to 
hold all information collected from the eligible trials. Items in the master dataset included 
age, race/ethnicity, overall survival, outcome (death), initial staging, Gleason Score, baseline 
laboratory data, prior therapy, disease extent (bone, lymph node, and visceral organ 
involvement), PSA response during therapy. Race/ethnicity of the patients was categorized 
into white, black, Hispanic, Asian and others. As not all trials provided the exact age of the 
patient, age was categorized into three groups: 18 to 64 years, 65 to 74 years, and 75 years 
and above. Overall survival was defined as the time from the date of randomization to the 
date of death. Baseline laboratory data was defined as laboratory tests taken within 14 days 
prior to randomization; if multiple lab tests were taken within the defined period, the lab test 
closest to randomization would be recorded as baseline. A PSA response was defined as 
having a greater or equal to 50% PSA decline from the baseline PSA level within 12 weeks 





2.4 Imputation of missing values 
In order to retain the power of the analyses, Markov chain Monte Carlo (MCMC) method 
was used to impute missing laboratory data 32, approximating the distribution of the observed 
variables. Before MCMC imputation, all laboratory data were natural log transformed to 
avoid generation of negative values from the imputation. Baseline laboratory data and 
important clinical characteristics were included in the imputation model. 
 
2.5 Comparison of baseline characteristics 
Comparison of baseline characteristics was performed between black and white patients. Chi-
square test was used to compare ordinal variables. Wilcoxon rank-sum test was used to 
compare continuous variables. Comparison of imputed and unimputed laboratory data was 
also performed using Wilcoxon rank-sum test. 
 
2.6 Comparison of overall survival 
The overall survival of the patient groups was estimated by the Kaplan-Meier method and 
statistical significance was assessed by log-rank test. A random-effect model was used to 
estimate the hazard ratio pooled over the trials. The effect of variables on overall survival 
was performed using mixed-effect Cox proportional hazard model. The fixed effects of the 
primary variable of interest: race (black vs white), as well as age, disease stage, and extent, 
prior therapy, baseline laboratory data were analyzed in the models, whereas the random 
effect of the individual clinical trials was also tested. The interaction between race and other 





2.7 Selection of the Cox models 
A Cox model using the imputed dataset that included all variables was first constructed. A 
stepwise approach by taking out one variable at a time, starting from the least significant one, 
was performed to select the desirable model. Non-significant variables that alter the HR for 
the main effect of interest (black vs white) by equal or greater than 3% were included in the 
model. Significant variables that change the main effect of interest by less than 3% were 
dropped from the model. Age and visceral disease were fixed in the model regardless of 
significance. The next step was to construct the final model, which included the previously 
selected variables but excluded those having a missing value greater than 10%, using non-
imputed data. A sensitivity analysis comparing the main effect of interest between the final 
model and the one using imputed data was performed.  
 
2.8 Prognostic value of PSA response on overall survival 
The prognostic value of PSA response was tested using the mixed-effect Cox model. PSA 
response was added as a fixed-effect variable in the selected Cox model described in the prior 
section. The difference in prognostic value of PSA response between race was examined by 
an interaction model. The fit of the original (main effects) model  vs. the interaction model 
was compared using likelihood ratio test.  
 
2.9 The incidence of PSA response 
A mixed-effect logistic regression model was used to test the difference in incidence of PSA 
response between black and white race. The same stepwise approach described in the 
“Selection of Cox models” section was used for selecting the desirable logistic regression 
model. The interaction between race and other variables was tested by adding an interaction 




3.1 Trials selected for analyses 
Data from 13 CRPC trials were accessible from Project Data Sphere. Twelve of the thirteen 
trials enrolled patients with metastatic CRPC, and among those, nine focused on patients who 
had not received prior chemotherapy. Docetaxel and prednisone (with or without an 
additional placebo) were given as the comparator arm treatment in four trials [ASCENT2 
(NCT00273338), MAINSAIL (NCT00988208), VENICE (NCT00519285), and ENTHUSE-
M1C (NCT00617669)]. Individual-level, de-identified patient data from the four trials were 
included for analyses (Table 1). 
 
3.2 Patient demographics 
A total of 2070 men were in the comparator arm of the four trials, including 1721 white, 96 
black, 14 Hispanic, 115 Asian, and 69 men of other race. The race of fifty-five out of the 
2070 men was missing. The age distribution, BMI, proportion of visceral and bone disease, 
prior therapy received were similar between white and black patients. Black men had a 
significantly lower proportion of lymph node or soft tissue disease; lower baseline 
hemoglobin and total bilirubin concentration; higher baseline PSA level, serum calcium 
concentration, serum creatinine, blood lymphocyte count, and serum creatinine (Table 2). 
 
3.3 Imputation of laboratory data 
All laboratory data were natural log transformed before MCMC imputation. Variables 
included in the MCMC model were the individual trial, age, race, presence of visceral 
disease, baseline PSA, ALP, LDH, albumin, total-bilirubin, analine aminotransferase 
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creatinine, hemoglobin, platelet count, and neutrophil/lymphocyte ratio. The number of 
imputed values generated for each lab variable is in Table 3. 
 
3.4 Comparison of overall survival between black and white men 
The median OS for black and white patients was 651 days (95% CI 588-743) and 592 days 
(95% CI 568-651), respectively (Fig. 1). No difference in OS was detected between the two 
races by log-rank test (P=0.708). The hazard ratio for death, comparing black to white race 
was 0.63 (95% CI 0.3-1.35) in the ASCENT-2 trial, 0.67 (0.24-1.85) in the MAINSAIL trial, 
0.94 (95% CI 0.55-1.61) in the VENICE trial, and 1.21 (0.77-1.91) in the ENTHUSE-M1C 
trial. The combined hazard ratio in the random effect model was 0.96 (95% CI 0.71-1.31, 
p=0.454) (Fig. 2). The hazard ratio for death, comparing black to white race in the 
unadjusted, mixed-effect Cox model was 0.90 (95% CI 0.67-1.22, p=0.510). After stepwise 
selection, the variables included in the model using imputed data were race, age, baseline 
PSA, ALP, LDH, Hb, receipt of prior gonadotropin, visceral disease and lymph node and/or 
soft tissue disease. As LDH was the only variable with a missing value greater than 10%, it 
was taken out from the model using the non-imputed data. Comparing the effect of race on 
OS between the model using the imputed data and the model without LDH using the non-
imputed data, the difference in hazard ratio was less than 3% (HR 0.88 vs 0.86). Thus, the 
model using the non-imputed data was the final Cox model (Table 4). Overall, OS was 
comparable between black and white men across models. Black men had a slightly lower 
hazard of death, but the effect was non-significant. 
 
3.5 Interaction between race and age; race and visceral disease on overall survival 
The interaction models were based on the final Cox model. The hazard ratios for death, 
comparing black and white men in the 18-64 years, 65-74 years, and ≥ 75 years age groups 
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were 0.82 (95% CI 0.48-1.41, p=0.477), 1.10 (95% CI 0.71-1.72, p=0.670), and 0.51 (0.23-
1.15, p=0.104). A trend of favorable survival in black men older or equal to 75 years was 
identified, but the interaction was not significant (Table 5.). No significant interaction 
between race and visceral disease was detected. The hazard ratios for death comparing black 
to white men in visceral disease and non-visceral disease were 0.96 (95% CI 0.42-2.17, 
p=0.917) and 0.84 (95% CI 0.60-1.19, p=0.323) (Table 6). The fit of the model was not 
significantly improved in the interaction models after examined by likelihood ratio test 
(p=0.219 for the race*age model; p=0.777 for the race*visceral disease model).  
 
3.6 Prognostic value of PSA response 
PSA response was added as an independent variable to the final Cox model. The hazard ratio 
for death comparing patients with PSA response to those without was 0.55 (95% CI 0.48-
0.63, p<0.001) in all patients, 0.54 (95% CI 0.47-0.62, p<0.001) in white men, and 1.00 (95% 
CI 0.49-2.05, p=0.997) in black men. To test whether there is a difference in the prognostic 
value of PSA response between black and white men, an interaction term between race and 
PSA response was added to the model. The overall survival difference between PSA 
responders and non-responders was more prominent in white men compared to black men 
(Table 7 and Fig. 3). However, the interaction term (p=0.258) and the likelihood ratio test 
(p=0.259) comparing the interaction model to the original model were not significant.  
 
3.7 Incidence of PSA response 
The odds ratio for PSA response, comparing black to white men was 1.21 (95% CI 0.47-2.66) 
in the ASCENT-2 trial, 0.98 (0.42-2.27) in the MAINSAIL trial, 1.46 (95% CI 0.52-4.08) in 
the VENICE trial, and 1.12 (0.47-2.66) in the ENTHUSE-M1C trial. The combined odds 
ratio in the random effect model was 1.16 (95% CI 0.74-1.81, p=0.454) (Fig. 4). The odds for 
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having PSA response was higher in black men compared to white men in the unadjusted 
mixed-effect logistic regression model (Odds ratio: 1.14, 95% CI 1.00-1.29, p=0.044). After 
stepwise selection, the variables included in the mixed-effect logistic regression model using 
imputed data were race, age, baseline PSA, ALP, LDH, Hb, total bilirubin, creatinine, 
visceral disease and receipt of radiation therapy. As LDH was the only variable with a 
missing value greater than 10%, it was taken out from the model using the non-imputed data. 
Comparing the effect of race on the incidence of PSA response between the model using the 
imputed data and the model without LDH using the non-imputed data, the difference in odds 
ratio was less than 3% (OR 1.29 vs 1.30). Thus, the model using the non-imputed data was 
selected as the final logistic regression model (Table 8). Overall, black men were more likely 
to have a PSA response during docetaxel/prednisone treatment compared to white men across 
models. 
 
3.8 Interaction between race and age; race and visceral disease on PSA response 
The interaction models were based on the final logistic regression model. Black men were 
more likely to have PSA response compared to white men within the three age groups, 
particularly forages 18-64 years (OR 1.70, 95% CI 0.98-2.96, p=0.060), but the effects were 
not significant (Table 9). The interaction terms between race and age were non-significant 
(race*65-74yr: p=0.211; race*≥75yr: p=0.514) and did not improve the fit of the model 
(likelihood ratio test p=0.632). Black men had a higher tendency to have PSA response 
compared to white men in both visceral disease (OR 1.27, 95% CI 1.13-1.43, p<0.001) and 
non-visceral disease (OR 1.61, 95% CI 0.88-2.96, p=0.124) (Table 10). The interaction term 
between race and visceral disease was not significant (p=0.486) and adding it did not 




3.9 Summary of results 
Overall, among patients enrolled in the comparator arm of the four CRPC trials, black men 
had a non-significantly more favorable OS compared to white men. The effect was consistent 
across age groups and patients with or without visceral disease (Fig.5). Having PSA response 
within 12 weeks of randomization was a strong favorable prognostic indicator in white men, 
but not in black men (Fig. 6). Black men had a significantly higher tendency for having PSA 
response. A similar effect was observed in all age groups and patients with or without 




In the present study, we examined the effect of race, comparing black to white men, on the 
overall survival of docetaxel treated patients with CRPC using data from the comparator arm 
of four phase III clinical trials. Given that all patients analyzed were chemotherapy-naive 
before trial enrollment and were assigned to docetaxel and prednisone, we were able to 
isolate the effect of race in a setting with fewer confounders. The detailed history of prior 
therapy, the extent of the disease and baseline lab data recorded in clinical trials allowed 
adjustment for prognostic factors and increased validity.  
 
Data from the four CRPC trials included in the present study suggested that black men had a 
significantly higher baseline PSA level and lower baseline Hemoglobin. These findings were 
consistent with those from prior studies 22,24,33,34. However, no difference in ALP, LDH, and 
proportion of visceral metastasis was found between the two races in the present or the two 
prior studies. The discordance between the PSA, Hemoglobin and the other disease severity 
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indicator might suggest that the racial difference of baseline PSA and hemoglobin is 
biological. This hypothesis is supported by prior studies that addressed racial differences in 
serum PSA and hemoglobin 35,36. 
 
We found a comparable OS between black and white CRPC patients (651 vs 592 days, 
p=0.708), and a tendency of lower risk of death in black men, though not statistically 
significant (HR 0.86, 0.62-1.18). The findings aligned with prior evidence 22-24. The recent 
study by Halabi et al. included three of the four trials in the present study along with six other 
trials; patients in both experimental and control arms were included for analysis to reach a 
sizable black patient number. The favorable outcome in black men was significant in their 
analyses, but the effect size (HR 0.81 0.72-0.91, p<0.001) was similar to our result. When the 
trials were examined separately, the risk of death in black men was significant in only two 
out of the nine trials, suggesting that the effect is relatively small and could be heterogeneous 
across trials24. We also analyzed whether the effect of race differs across age and in the 
presence of visceral metastasis via interaction models, which was not performed in previous 
similar studies. The difference in risk of death seemed to be most prominent in patients ≥75 
years, but the sample size within the subgroup was small to make such interpretation. As 
Halabi et al. demonstrated that the risk of death differs between age groups, it would be 
worth exploring the interaction of race and age within a larger population. On the other hand, 
the effect of race on OS was similar in patients with or without visceral metastases.  
 
Following the prior studies that suggested a better outcome in black men with CRPC, the 
current attempted to explore the mechanism of such findings by comparing PSA response 
between black and white patients. We found that black men were more likely to have a PSA 
response than white men (OR 1.30, 95% CI 1.17-1.46, p<0.001). This was observed 
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consistently across age groups and patients with or without visceral metastases. The majority 
of studies on the racial disparity in serum PSA level focused on men without prostate cancer 
and its application on PSA screening 35,37,38. There are limited data on the racial disparity in 
PSA dynamics after treatment in prostate cancer. A study found that PSA nadir and PSA 
doubling time after hormone therapy or hormone therapy withdraw did not differ between 
black and white men 39. Another study showed that PSA outcome after radical prostatectomy 
was comparable between black and white patients 40. In a small case series, PSA decline in 
black men with locally advanced prostate cancer was similar to that of white men after 
neoadjuvant chemohormonal therapy 41. McGuire et al. showed that African-American men 
were less likely to experience normalization of PSA after neoadjuvant androgen deprivation 
therapy 42. Possibly the only published data to date on the racial disparity in PSA dynamics 
after CRPC treatment is a case-control study by Ramalingam et al. 43. White patients with 
CRPC diagnosed at a medical center between 2008 and 2015 were matched 2:1 to black 
patients as control based on docetaxel exposure. The proportion of PSA response was 
significantly higher in black men compared to white men (68.9% vs 48.9% p=0.028). Despite 
studying treatments other than docetaxel, the higher proportion of PSA response in black men 
in these studies aligned with our findings. As PSA response was identified as a prognostic 
factor for prostate cancer 25-28, the higher tendency of having PSA response in black men 
could be one explanation to their favorable survival.  
 
Interestingly, we found that the prognostic value of PSA response may be different between 
black and white men in the interaction model. While PSA response was a strong favorable 
indicator for survival in white men (HR for death 0.54, 95% CI 0.47-0.62, p<0.001), the 
effect was non-significant in black men (HR 0.78 95% CI 0.42-1.45, p=0.423). To our 
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knowledge, the present study is the first to address this issue. The mechanism and implication 
of this observation warrant further investigation.  
 
The major limitation of the present study was the small number of black CRPC patients 
included, which hindered the power of the analyses. The data used in the study was limited to 
that available from the Project Data Sphere and the sample size further lowered after we 
restricted to patients who received docetaxel and prednisone. We believe that a valid 
inference could only be made in a controlled clinical trial setting, in which the influence of 
residual confounders is minimized by randomization. The different definition of race could 
be a limitation. The four trials included in the study enrolled participants over a wide 
geographic region, including America, Europe, and Asia, and the definition of black race may 
vary across trials. Only one of the four trials differentiated non-Hispanic white with Hispanic 
white, thus the composition of white men in this study could also be heterogeneous.  Another 
challenge with the dataset was missing data. Potential prognostic variables such as prior 
surgical history (prostatectomy, orchidectomy), body-mass index, LDH, albumin neutrophil-
lymphocyte ratio were not collected in one or more of the trials. In order to retain sample size 
while including important variables with a high proportion of missing values, we used 
multiple chain imputation for missing lab data. But, a  sensitivity analysis showed that the 
main effect of interest was not altered when using imputed data.  
 
Only 5% of the study population was black; the proportion was similar to that previously 
reported 16. Underrepresentation of black patients in cancer clinical trials could be attributed 
to various socioeconomic and cultural factors 18,19. The aim of the present study was not only 
to add knowledge to the racial disparity in CRPC but also to raise awareness of the 
underrepresentation of black men in prostate cancer trials. There has been growing evidence, 
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including that provided in this study, indicating that black men participated in CRPC trials 
have comparable or even more favorable outcome 22-24. We hope that delivering such 
information to both the black community and physicians will foster participation as well as 




5 Figure Legend 
Table 1. Information on the four CRPC trials included for analysis 
 ASCENT-2 MAINSAIL VENICE ENTHUSE-M1C 
ClinicalTrials.gov  
registry number NCT00273338 NCT00988208 NCT00519285 NCT00617669 

















No. of pts. in the comparator arm by 
race, N (%)     
White 419 (88) 433 (92) 538 (97) 331 (70) 
Black 32 (7) 25 (5) 17 (3) 22 (6) 
Hispanic 14 (3) 0 (0) 0 (0) 0 (0) 
Asian 5 (1) 0 (0) 36 (6) 74 (16) 
Other 7 (1) 13 (3) 7 (1) 43 (9) 
Participating countries/regions 
Canada, Czech Republic, 
Former Serbia and 
Montenegro, Germany, 
Hungary, Puerto Rico, 
Romania, Slovakia, United 
States 
Argentina, Australia, Brazil, 
Canada, Czech Republic, 
Finland, France, Germany, 
Hungary, India, Italy, Korea, 
Netherlands, Peru, Poland, 
Portugal, Romania, Russian 
Federation, Serbia, South 
Africa, Spain, Sweden, 
Switzerland, Taiwan, United 
Kingdom, United States 
Argentina, Australia, Belgium, 
Brazil, Canada, Chile, Croatia, 
Czech Republic, Denmark, 
Estonia, France, Germany, 
Hong Kong, Hungary,  
Israel,   Italy,   Korea, 
Netherlands, Poland, Portugal, 
Russian Federation, Singapore, 
South Africa, Spain, Sweden, 
Switzerland, Taiwan, Turkey, 
Ukraine, United Kingdom, 
United States 
Argentina, Australia, Brazil, 
Canada, Czech Republic, 
Finland, France, Germany, 
Hungary, India, Italy, Korea, 
Netherlands, Peru, Poland, 
Portugal, Romania, Russian 
Federation, Serbia, South 
Africa, Spain, Sweden, 
Switzerland, Taiwan, United 












P-value Missing % 
Age group, N (%)     
18-64 years 34 (31) 532 (35) 
0.622 -- 65-74 years 42 (45) 783 (44) 
≥75 years 20 (24) 406 (21) 
BMI (m2/kg), median (IQR) 27.9 (24.6-31.0) 27.8 (25.3-30.8) 0.956 362 (20) 
Disease extent, N(%)     
Visceral metastasis 12 (13) 319 (19) 0.136 -- 
Bone metastasis 79 (81) 1468 (85) 0.278 -- 
Lymph node/soft tissue metastasis 34 (35) 827 (48) 0.016 -- 
Prior therapy     
Gonadotropin (ADT) 71 (76) 1353 (79) 0.425 10 (1) 
Anti-androgen 63 (67) 1289 (75) 0.074 10 (1) 
Glucocorticoid 33 (35) 631 (37) 0.735 10 (1) 
Corticosteroid 8 (9) 181 (11) 0.526 10 (1) 
Bisphosphonate 31 (33) 651 (38) 0.328 10 (1) 
Imidazole 12 (13) 160 (9) 0.271 10 (1) 
Estrogen 5 (5) 148 (9) 0.260 10 (1) 
Radiation therapy 54 (56) 1026 (60) 0.513 -- 
Prostatectomy 18 (24) 406 (29) 0.367 353 (19) 
Orchidectomy 15 (20) 222 (16) 0.328 353 (19) 
Baseline lab data, median (IQR)     
PSA (ng/mL) 123 (49-416) 85 (31-243) 0.010 18 (1) 
ALP (U/L) 121 (85-218) 126 (83-260) 0.634 19 (1) 
Ca (mmol/L) 2.38 (2.33-2.47) 2.34 (2.25-2.42) <0.001 24 (1) 
LDH (U/L) 200 (180-236) 208 (176-269) 0.711 598 (33) 
Albumin (g/L) 42 (39-44) 43 (40-45) 0.308 481 (27) 
Neutrophil (K/mm3) 4.40 (3.01-6.01) 4.70 (3.60-6.52) 0.060 46 (3) 
Lymphocyte (K/mm3) 1.56 (0.79-2.06) 1.09 (0.73-1.61) 0.020 1040 (57) 
Hemoglobin (g/dL) 11.9 (11.0-12.9) 12.7 (11.6-13.6) <0.001 34 (2) 
Creatinine (µmol/L) 97 (80-111) 82 (71-97) <0.001 17 (1) 






Table 3. Missing laboratory values 
Variables 
Observations 
Complete Incomplete Imputed 
PSA 1798 19 19 
ALP 1798 19 19 
LDH 1219 598 598 
ALT 1789 28 28 
Albumin 1336 481 481 
Hemoglobin 1783 34 34 
N/L ratio 773 1044 1044 
Platelet 1771 46 46 
Creatinine 1800 17 17 






Table 4. Mixed-effect Cox models on OS 
 Full model, imputed data† Selected model, imputed data† Selected model, non-imputed data*† 
No. of patients 1807 1807 1751 
No. black/white 94/1713 94/1713 89/1662 
Variables HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value 
Race 
(black vs white) 0.87 0.63-1.20 0.388 0.88 0.64-1.20 0.416 0.86 0.62-1.18 0.339 
Age group          
18-64 1 -- -- 1 -- -- 1 -- -- 
65-74 0.90 0.77-1.05 0.186 0.92 0.79-1.07  0.91 0.78-1.06 0.209 
≥ 75 1.03 0.85-1.25 0.759 1.06 0.88-1.28  1.05 0.87-1.26 0.624 
PSA 1.05 1.00-1.11 0.035 1.05 1.00-1.10 0.047 1.05 1.00-1.10 0.045 
ALP 1.36 1.22-1.51 <0.001 1.35 1.22-1.50 <0.001 1.42 1.30-1.54 <0.001 
LDH 1.21 0.93-1.57 0.148 1.21 0.94-1.56 0.138    
Albumin 0.43 0.20-0.91 0.028       
Hb 0.23 0.11-0.46 <0.001 0.18 0.10-0.34 <0.001 0.16 0.09-0.28 <0.001 
N/L ratio 1.04 0.92-1.18 0.471       
Creatinine 1.08 0.81-1.44 0.583       
Total-bilirubin 1.00 0.85-1.17 0.962       
Anti-androgen 1.06 0.86-1.32 0.572       
Glucocorticoid 0.88 0.68-1.13 0.315       
Gonadotropin 0.73 0.62-0.87 <0.001 0.75 0.64-0.89 0.001 0.77 0.65-0.92 0.003 
Bisphosphonate 0.91 0.79-1.05 0.197       
Corticosteroid 1.08 0.79-1.47 0.632       
Imidazole 1.00 0.77-1.29 0.985       
Estrogen 0.78 0.61-1.00 0.047       
Radiation therapy 1.00 0.87-1.16 0.952       
Visceral disease 1.31 1.09-1.56 0.003 1.33 1.11-1.58 0.002 1.33 1.11-1.58 0.001 
Bone disease 1.05 0.82-1.35 0.691       
Lymph node/soft 
tissue disease 1.11 0.96-1.28 0.172 1.10 0.96-1.27 0.164 1.14 1.00-1.32 0.058 
*  Final model of choice 






Table 5. Interaction between race and age on overall survival 
Mixed-effect Cox model with interaction term† 
 
 Black White 
HR 95% CI p-value 
 Events No. of patients 
Events No. of 
patients 
18-64 years 
black vs white 14 33 280 515 0.82 0.48-1.41 0.477 
65-74 years 
black vs white 21 37 343 752 1.10 0.71-1.72 0.670 
≥ 75 years 
black vs white 6 19 190 395 0.51 0.23-1.15 0.104 
PSA     1.05 1.00-1.11 0.039 
ALP     1.42 1.30-1.54 <0.001 
Hb     0.16 0.09-0.28 <0.001 
Gonadotropin     0.78 0.66-0.92 0.004 
Visceral disease     1.33 1.12-1.59 0.001 
Lymph node/soft tissue disease     1.14 1.00-1.32 0.058 






Table 6. Interaction between race and visceral disease on overall survival 
Mixed-effect Cox model with interaction term† 
 Black White 
HR 95% CI p-value 
 Events No. of patients 
Events No. of 
patients 
Non-visceral disease 35 78 653 1351 0.84 0.60-1.19 0.323 
Visceral disease 6 11 160 311 0.96 0.42-2.17 0.917 
18-64 years     1 -- -- 
65-74 years     0.91 0.78-1.06 0.211 
≥ 75 years     1.05 0.87-1.26 0.628 
PSA     1.05 1.00-1.10 0.045 
ALP     1.42 1.30-1.54 <0.001 
Hb     0.16 0.09-0.28 <0.001 
Gonadotropin     0.77 0.65-0.92 0.003 
Lymph node/soft tissue disease     1.14 0.99-1.31 0.060 






Table 7. Interaction between race and PSA response on overall survival 
Mixed-effect Cox model with interaction term† 
 Responders Non-responders 
HR 95% CI p-value 
 Events No. of patients 
Events No. of 
patients 
Black 
PSA responder vs non-responder 20 46 20 41 0.78 0.42-1.45 0.423 
White 
PSA responder vs non-responder 364 825 439 812 0.54 0.47-0.62 <0.001 
18-64 years     1 -- -- 
65-74 years     0.92 0.79-1.08 0.309 
≥ 75 years     1.04 0.87-1.25 0.686 
PSA     1.03 0.98-1.08 0.272 
ALP     1.46 1.34-1.58 <0.001 
Hb     0.17 0.09-0.30 <0.001 
Gonadotropin     0.76 0.64-0.91 0.003 
Viseral disease     1.34 1.12-1.59 0.001 







Table 8. Mixed-effect logistic regression models on the tendency of PSA response 
 Full model, imputed data† Selected model, imputed data† Selected model, non-imputed data*† 
No. of patients 1774 1784 1716 
No. black/white 90/1684 92/1692 87/1629 
Variables OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Race 
(black vs white) 1.29 1.16-1.44 <0.001 1.29 1.17-1.43 <0.001 1.30 1.17-1.46 <0.001 
Age group          
18-64 1 -- -- 1 -- -- 1 -- -- 
65-74 1.09 0.96-1.23 0.191 1.08 0.96-1.22 0.215 1.09 0.95-1.25 0.218 
≥ 75 0.93 0.73-1.18 0.538 0.93 0.74-1.19 0.583 0.93 0.75-1.15 0.517 
PSA 0.97 0.91-1.04 0.441 0.97 0.91-1.03 0.333 0.96 0.90-1.03 0.238 
ALP 1.09 0.92-1.29 0.309 1.09 0.95-1.25 0.237 1.06 0.94-1.19 0.358 
LDH 0.83 0.70-0.98 0.028 0.84 0.74-0.97 0.015    
Albumin 1.28 0.39-4.09 0.676       
Hb 2.87 1.47-5.59 0.002 3.76 1.72-8.19 0.001 4.34 2.26-8.35 <0.001 
N/L ratio 0.98 0.79-1.22 0.863       
Creatinine 1.05 0.82-1.33 0.710 1.06 0.81-1.38 0.677 1.05 0.81-1.37 0.699 
Total-bilirubin 1.28 1.05-1.55 0.013 1.26 1.06-1.49 0.009 1.22 1.04-1.44 0.016 
Anti-androgen 1.19 0.93-1.41 0.213       
Glucocorticoid 1.08 0.84-1.39 0.544       
Gonadotropin 1.20 0.93-1.54 0.164       
Bisphosphonate 0.93 0.82-1.04 0.210       
Corticosteroid 0.86 0.17-4.48 0.862       
Imidazole 0.76 0.65-0.8 <0.001       
Estrogen 0.98 0.76-1.26 0.845       
Radiation therapy 1.24 1.01-1.53 0.041 1.24 1.01-1.53 0.037 1.29 1.01-1.64 0.039 
Visceral disease 1.15 0.88-1.50 0.293 1.15 0.89-1.48 0.293 1.13 0.82-1.55 0.451 
Bone disease 0.99 0.77-1.27 0.920       
Lymph node/soft 
tissue disease 1.04 0.79-1.38 0.766       
*  Final model of choice 






Table 9. Interaction between race and age on the tendency of PSA response 
Mixed-effect logistic regression model with interaction term† 
 
 Black White 
ＯR 95% CI p-value 
 Events No. of patients 
Events No. of 
patients 
18-64 years 
black vs white 18 31 253 508 1.70 0.98-2.96 0.060 
65-74 years 
black vs white 19 38 384 731 1.05 0.59-1.86 0.870 
≥ 75 years 
black vs white 9 18 184 390 1.31 0.81-2.14 0.275 
PSA     0.96 0.90-1.03 0.246 
ALP     1.06 0.94-1.19 0.355 
Hb     4.39 2.32-8.31 <0.001 
Total-bilirubin     1.22 1.04-1.44 0.014 
Creatinine     1.06 0.81-1.38 0.695 
Radiation therapy     1.29 1.01-1.63 0.038 
Visceral disease     1.29 0.82-1.54 0.456 







Table 10. Interaction between race and visceral disease on the tendency of PSA response 
Mixed-effect logistic regression model with interaction term† 
 
 Black White 
OR 95% CI p-value 
 Events No. of patients 
Events No. of 
patients 
Non-visceral disease 40 77 660 1323 1.27 1.13-1.43 <0.01 
Visceral disease 6 10 161 306 1.61 0.88-2.96 0.124 
18-64 years        
65-74 years        
≥ 75 years        
PSA     0.97 0.90-1.03 0.237 
ALP     1.06 0.94-1.19 0.354 
Hb     4.33 2.25-8.36 <0.001 
Total-bilirubin     1.22 1.04-1.44 0.015 
Creatinine     1.05 0.81-1.37 0.699 
Radiation therapy     1.29 1.01-1.63 0.038 














































































Figure 5. HR for death, comparing black to white men by age group and visceral disease in 






































































Figure 7. OR for PSA response, comparing black to white men by age group and visceral 
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